Back
AIM ImmunoTech 10K Form
Sell
22
AIM
AIM ImmunoTech
Last Price:
0.25
Seasonality Move:
-2.83%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2021-05-17 | 10Q | AIM/AIM ImmunoTech Quarterly |
2021-03-31 | 10K | AIM/AIM ImmunoTech Annual |
2020-11-12 | 10Q | AIM/AIM ImmunoTech Quarterly |
2020-08-14 | 10Q | AIM/AIM ImmunoTech Quarterly |
2020-05-14 | 10Q | AIM/AIM ImmunoTech Quarterly |
2020-03-30 | 10K | AIM/AIM ImmunoTech Annual |
Receive AIM News And Ratings
See the #1 stock for the next 7 days that we like better than AIM
AIM Financial Statistics
Sales & Book Value
Annual Sales: | $202K |
---|---|
Cash Flow: | $-3.24M |
Price / Cash Flow: | 0 |
Annual Sales: | $0.11 |
Price / Book: | 2.59 |
Profitability
EPS (TTM): | -0.57000 |
---|---|
Net Income (TTM): | $-28.05M |
Gross Margin: | $160K |
Return on Equity: | -189.75% |
Return on Assets: | -124.35% |
AIM ImmunoTech Earnings Forecast
Key AIM ImmunoTech Financial Ratios
- The Gross Profit Margin over the past 29 years for AIM is 79.21%.
- The Selling, General & Administrative Expenses for AIM have been equal to 10,463.86% of Gross Profit Margin.
- The Research & Development expenses have been 5,415.35% of Revenue.
- The Interest Expense is 0.00% of Operating Income.
- The Net Earning history of AIM is -14,337.62% of Total Revenues.
- Per Share Earnings over the last 29 years have been positive in 17 years.
AIM ImmunoTech Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NYAM |
---|---|
Industry: | Biotechnology |
Sector: | Health Care |
Current Symbol: | AIM |
CUSIP: | 00901B |
Website: | aimimmuno.com |
Debt
Debt-to-Equity Ratio: | 0.43 |
---|---|
Current Ratio: | 1.17 |
Quick Ratio: | 1.14 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 0 |
AIM Technical Analysis vs Fundamental Analysis
Sell
22
AIM ImmunoTech (AIM)
is a Sell
Is AIM ImmunoTech a Buy or a Sell?
-
AIM ImmunoTech stock is rated a Sell
The current AIM ImmunoTech [AIM] share price is $0.25. The Score for AIM is 22, which is 56% below its historic median score of 50, and infers higher risk than normal.